Press release
Dyskinesia Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight
"Dyskinesia Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Dyskinesia Market.
The Dyskinesia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Dyskinesia Pipeline Report: https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Dyskinesia treatment therapies with a considerable amount of success over the years.
• Dyskinesia companies working in the treatment market are PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others, are developing therapies for the Dyskinesia treatment
• Emerging Dyskinesia therapies in the different phases of clinical trials are- PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others are expected to have a significant impact on the Dyskinesia market in the coming years.
• In November 2024, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) showcased data from the KINECT®-4 long-term study, revealing that nearly 60% of participants achieved tardive dyskinesia remission after 48 weeks of once-daily treatment with INGREZZA® (valbenazine) capsules. The findings were presented at the 2024 Psych Congress in Boston under the poster titled "Remission of Tardive Dyskinesia in Patients Receiving Long-Term Valbenazine Treatment" (Poster #98).
• In March 2024, Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced the initiation of a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-1065890 in healthy adults. NBI-1065890 is an investigational oral selective inhibitor of vesicular monoamine transporter-2 (VMAT2), being explored for the treatment of certain neurological and neuropsychiatric conditions. "Neurocrine's extensive expertise in VMAT2 inhibition is demonstrated through the successful development of valbenazine for tardive dyskinesia and chorea in Huntington's disease
Dyskinesia Overview
A movement disorder called dyskinesia frequently manifests as uncontrollably shaking, ticing, or trembling. People who have Parkinson's disease frequently develop the condition as a result of drugs that overstimulate their dopamine receptors, increasing this neurotransmitter in the brain.
Get a Free Sample PDF Report to know more about Dyskinesia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Dyskinesia Drugs Under Different Phases of Clinical Development Include:
• P-1037 IS : Parion Sciences
• NLX 112 : Neurolixis
• DSP-9632P : Sumitomo Dainippon Pharma
• JM-010 : Contera Pharma
• PCT-3012: PolyCore Therapeutics
• Mesocarb: Melior Pharmaceuticals
• ML 007: MapLight Therapeutics
• LY 03015: Luye Pharma Group
• JM-010 : Contera Pharma
• NLX 112: Neurolixis
• CPL 500036: Celon Pharma
Dyskinesia Route of Administration
Dyskinesia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Dyskinesia Molecule Type
Dyskinesia Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
Dyskinesia Pipeline Therapeutics Assessment
• Dyskinesia Assessment by Product Type
• Dyskinesia By Stage and Product Type
• Dyskinesia Assessment by Route of Administration
• Dyskinesia By Stage and Route of Administration
• Dyskinesia Assessment by Molecule Type
• Dyskinesia by Stage and Molecule Type
DelveInsight's Dyskinesia Report covers around 22+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Dyskinesia product details are provided in the report. Download the Dyskinesia pipeline report to learn more about the emerging Dyskinesia therapies
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Dyskinesia Therapeutics Market include:
Key companies developing therapies for Dyskinesia are - Teva Pharmaceutical, Neurocrine Biosciences, Inc, Sun Pharmaceutical, SteriMax Inc., Adamas Pharmaceuticals, Inc, Sanis, AbbVie Inc, and others.
Dyskinesia Pipeline Analysis:
The Dyskinesia pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dyskinesia with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dyskinesia Treatment.
• Dyskinesia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dyskinesia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dyskinesia market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Dyskinesia drugs and therapies
https://www.delveinsight.com/sample-request/dyskinesia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Dyskinesia Pipeline Market Drivers
• Increase in prevalence of Dyskinesia, increase in the demand for disease specific novel treatment are some of the important factors that are fueling the Dyskinesia Market.
Dyskinesia Pipeline Market Barriers
• However, lack of understanding of the pharmacology of Dyskinesia, side-effects associated with drugs and other factors are creating obstacles in the Dyskinesia Market growth.
Scope of Dyskinesia Pipeline Drug Insight
• Coverage: Global
• Key Dyskinesia Companies: PolyCore Therapeutics, Melior Pharmaceuticals, MapLight Therapeutics, Luye Pharma Group, Contera Pharma, Neurolixis, Celon Pharma, and others
• Key Dyskinesia Therapies: PCT-3012, Mesocarb, ML 007, LY 03015, JM-010, NLX 112, CPL 500036, and others
• Dyskinesia Therapeutic Assessment: Dyskinesia current marketed and Dyskinesia emerging therapies
• Dyskinesia Market Dynamics: Dyskinesia market drivers and Dyskinesia market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dyskinesia Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight here
News-ID: 4210466 • Views: …
More Releases from DelveInsight Business Research
Brain Metastasis from Breast Cancer Pipeline 2025: MOA and ROA Insights, Clinica …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Brain Metastasis from Breast Cancer pipeline constitutes 10+ key companies continuously working towards developing 10+ Brain Metastasis from Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Brain Metastasis from Breast Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and…
Adrenal crisis Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsig …
DelveInsight's "Adrenal crisis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Adrenal crisis, historical and forecasted epidemiology as well as the Adrenal crisis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Adrenal crisis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Adrenal crisis Market Forecast
https://www.delveinsight.com/sample-request/adrenal-crisis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Advanced Renal Cell Carcinoma Pipeline 2025: Therapies Under Investigation, Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Advanced Renal Cell Carcinoma pipeline constitutes 50+ key companies continuously working towards developing 60+ Advanced Renal Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Advanced Renal Cell Carcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Hepatic Encephalopathy Market Positioned for Accelerated Development Through 203 …
DelveInsight's "Hepatic Encephalopathy Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Hepatic Encephalopathy, historical and forecasted epidemiology as well as the Hepatic Encephalopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Hepatic Encephalopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatic Encephalopathy Market Forecast
https://www.delveinsight.com/sample-request/hepatic-encephalopathy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Dyskinesia
Dyskinesia Market Emerging Trends and Growth Prospects 2034
Introduction
Dyskinesia, characterized by involuntary and uncontrolled movements, often arises as a side effect of long-term dopaminergic treatment in neurological disorders such as Parkinson's disease. As global cases of movement disorders continue to climb, so too does the need for therapies that effectively manage dyskinesia while preserving quality of life. The dyskinesia market has emerged as a critical segment of the wider central nervous system (CNS) therapeutics industry, shaped by aging…
Tardive Dyskinesia Market Report and Forecast 2024-2032
The tardive dyskinesia market size is anticipated to grow at a CAGR of 3.2 % during the forecast period of 2024-2032, driven by growing awareness about the importance of monitoring patients on long-term antipsychotic therapy for early signs of tardive dyskinesia in the major markets.
Tardive Dyskinesia: Introduction
Tardive dyskinesia is a neurological disorder characterized by involuntary, repetitive body movements. It primarily affects the face, causing grimacing, blinking, or lip-smacking, but can…
Dyskinesia Pipeline involves 40+ key companies continuously working towards deve …
"DelveInsight's Dyskinesia Pipeline Insight 2022 report provides comprehensive insights about 40+ companies and 45+ pipeline drugs in the Dyskinesia pipeline landscape"
It covers the Dyskinesia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dyskinesia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key takeaways from the Dyskinesia Pipeline Report
• DelveInsight's Dyskinesia Pipeline…
Primary Ciliary Dyskinesia Pipeline: Insights into Novel Key Pharma Companies, G …
DelveInsight's, "Primary Ciliary Dyskinesia Pipeline Insight, 2022," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Primary Ciliary Dyskinesia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. In the Primary Ciliary Dyskinesia Pipeline Report, detailed…
Tardive Dyskinesia Therapeutics- Pipeline Analysis 2018, Clinical Trials & Resul …
Tardive dyskinesia (TD) is an involuntary neurological movement disorder caused by the use of dopamine receptor blocking drugs which are prescribed to treat certain psychiatric or gastrointestinal conditions. Long-term use of these drugs may produce biochemical abnormalities in the area of the brain known as the striatum.
Download the sample report @ https://www.pharmaproff.com/request-sample/1106
The reasons that some people who take these drugs may get TD, and some people do not, is…
Tardive Dyskinesia Drugs Market
Tardive dyskinesia (TD) is a form of dyskinesia that is difficult to treat. It is a nerve disorder characterized by involuntary movements such as jaw, lips, and tongue, considered as grimacing, sticking the tongue out, and lip smacking. Some other symptoms are an individual experiencing involuntary movement of the lower and upper extremities and also breathing choking. According to Center for Drug Evaluation and Research, tardive dyskinesia can lead to…
